Form 8-K - Current report:
SEC Accession No. 0001437749-17-010130
Filing Date
2017-05-26
Accepted
2017-05-26 09:02:30
Documents
6
Period of Report
2017-05-26
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atrn20170525_8k.htm 8-K 28765
2 EXHIBIT 99.1 ex99-1.htm EX-99.1 11955
3 a4.jpg GRAPHIC 236940
4 a3.jpg GRAPHIC 242967
5 a2.jpg GRAPHIC 225907
6 a1.jpg GRAPHIC 109219
  Complete submission text file 0001437749-17-010130.txt   1164671
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51353 | Film No.: 17871908
SIC: 7389 Services-Business Services, NEC